Breast CancerMISSNCT04590560
What is the Best Interval to Screen Women 45-49 and 70-74 for Breast Cancer?
A study testing screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practice in people with Breast Cancer, run by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS at 4 sites in Italy.
Trial summary
Italian, multicenter, study aimed at defining the best interval for screening women 45-49 and 70-74 years for Breast Cancer (BC). This research project includes (1) a controlled, prospective randomized non-inferiority trial to determine the optimal screening interval for women aged 45-49, with and without high… Read more about this study
- Who is it for?
- Ages 45 to 49 years, women only
- Conditions the study is for
- Breast Cancer
- What is being tested?
- screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practice
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60,000 participants
- Where
- 4 sitesItaly
- Study dates
- 6 Feb 2020to Feb 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 to 49 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Women invited for their first or second mammography (45 or 46 y/o) presenting for screening;
- Willingness and ability to comply with scheduled visits;
- Written informed consent obtained prior to performing any protocol-related procedures.
Who cannot join
- Pregnancy status;
- Personal history of prior breast carcinoma, either invasive or ductal carcinoma in situ (DCIS) diagnosis;
- Ascertained heredo-familial risk according to the standard family history used in screening programs;
- Participation in another clinical trial on BC screening;
- Inability to provide signed informed consent.
Trial locations and contacts
4 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Chiara Zingaretti contact
Italy4 sites, 4 recruiting
- Not yet recruiting
Istituto per lo studio, la prevenzione e la rete oncologica (ISPRO)
Florence
Marco Zappa, MD
Paola Mantellini, MD
- Recruiting
AUSL Romagna
Forlì
Fabio Falcini, MD
- Recruiting
Irst Irccs
Meldola (FC), FC, 47014
Fabio Falcini, MD
- Not yet recruiting
AOU Città della Salute e della Scienza
Torino
Livia Giordano, MD
About this study
Official title: What is the Best Interval to Screen Women 45-49 and 70-74 for Breast Cancer
Italian, multicenter, study aimed at defining the best interval for screening women 45-49 and 70-74 years for Breast Cancer (BC). This research project includes (1) a controlled, prospective randomized non-inferiority trial to determine the optimal screening interval for women aged 45-49, with and without high mammographic density, (2) a retrospective data collection, with the same purpose, on screening performed by women aged 70-74, and (3) a qualitative research to define the best communication strategy.
Read the detailed description
According to the 2006 European guidelines, the target age for mammography screening is 50-69 years. For women aged 40-49, effectiveness is less and less certain. For those over 70, the most important concern is overdiagnosis. In Europe, so far, both age groups have been invited to screen only in a few countries and regional areas, including some Italian regions. Recently, new European guidelines have been published, developed in the framework of the European Commission Initiative on Breast Cancer. Although with caution, they recommend screening for both women aged 45-49 and those aged 70-74. The recommended interval is 2 or 3 years in the first case and 3 years in the second. The quality of the evidence on which these recommendations are based is defined as very low. Particularly for women aged 45-49, the new European guidelines indicate the need for a research effort, based on comparative studies, on the effectiveness of different screening intervals. This responsibility also falls on Italy, which is the only European country where women aged 45-49 are invited on an annual basis. Therefore, a research project is proposed which includes (1) a controlled, prospective randomized non-inferiority trial to determine the optimal screening interval for women aged 45-49, with and without high mammographic density, (2) a retrospective data collection, with the same purpose, on screening performed by women aged 70-74, and (3) a qualitative research to define the best communication strategy.
To define the best interval for screening women 45-49 years old a three-arm multicenter randomized non-inferiority trial will be conducted. Women signing the written informed consent will be randomized with a 1:1:1 ratio to:
Arm 1: 1-year screening interval; Arm 2: 2-year screening interval; Arm 3: tailored screening interval on the basis of breast density. Women with very dense breast (Breast Imaging-Reporting and Data System -BI-RADS- category D) will be referred to 1-year interval whereas women with less dense breast to 2-year interval (Breast Imaging-Reporting and Data System -BI-RADS- category A, B, C).
Enrollment will last 2.5 years and all women will be followed for 6 years. 60,000 women will be enrolled.
The primary objective is to compare the cumulative incidence of stage 2 or higher breast cancer between different screening intervals and this will be evaluated at the end of the 6-year follow-up period.
At the same time, data from all women registered in screening archives who have had a negative mammogram at the age of 69-71 years will be collected and analyzed. The data will be retrieved up to the age of 78 and will concern screening mammograms as well as other screening procedures (e.g. biopsies) and also mammograms performed outside the program. Data from screening and outpatient information systems as well as from cancer registries will be used.
To identify the best strategy to communicate changes in screening protocols, especially when the new protocol would be less intensive than the actual one, a qualitative research will be conducted. In particular the following steps will be considered:
- Focus groups for discussing, with women from target population and health care professionals, key arguments identified in a preliminary research (i.e. scientific literature and case-studies research), with particular focus on how they should be translated into communication strategies.
- Pre-test of the study's communication material through web-based semi-structured interviews to eligible women and key-informants.
- Assessment of the effectiveness of the communication material through web-based semi-structured interviews to participants, that may bring insights on how planning communication strategies for the implementation of new screening protocols.
- Conditions
- Breast Cancer
- Being tested
- screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practice
- Keywords
- Breast cancer, screening, diagnosis, mammography
- Medical subject headings
- Breast Neoplasms, Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practiceDiagnostic test
women will be screened for breast cancer using tomosynthesis and synthetic 2D mammography with an interval defined according to their randomization arm for a follow-up period of 6 years;
| Study group | Role | What they receive |
|---|---|---|
| 1-year screening interval | No intervention | Women will follow the normal screening program (they will be invited to screen every year) |
| 2-year screening interval | Experimental | Women will be invited to screen every two years Receives: Diagnostic Test: screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practice |
| 3-tailored screening interval | Experimental | the screening interval will be decided on the basis of breast density. Women with very dense breast (BI-RADS category D) will be referred to 1-year interval whereas women with less dense breast to 2-year interval (BI-RADS category A, B, C) Receives: Diagnostic Test: screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practice |
What is being measured
The primary outcome is the main question the study is designed to answer.
To compare the cumulative incidence of stage 2 or higher breast cancer between different screening intervals
Cumulative breast cancer risk will computed as the ratio between the number of stage 2 or higher cancers and the total number of women in the arm. The comparison between arms will be performed using the two proportion Z-test. 95% confidence intervals will also be computed
Measured: 6 years
Secondary outcomes (9)
Participation in screening
number of participating women within 3 months since invitation)/(total invited women). It will be computed for each screening round and overall as average of round participation
Measured: 6 years
contamination proportion (use of mammography) within two screening rounds (in women referred to 2-year interval)
number of women referred to 2-year interval and performing a mammogram within two screening round)/number of women referred to 2-year interval The indicator will be computed only for women randomized to arm 2 and for women referred to 2-year arm in arm 3
Measured: 6 years
Breast cancer detection
number of women with BC diagnosis at screening / number of total screened women
Measured: 6 years
overall recall rate
number of women recalled for further assessment/ number of total screened women.
Measured: 6 years
rate of recall with an invasive procedure (biopsy)
number of women recalled for further assessment with a biopsy/ number of total screened women
Measured: 6 years
interval Breast Cancer rate
number of cancers occurring after a negative mammography and before the date of the next planned appointment/ number of total screened women
Measured: 6 years
cumulative Breast Cancer incidence
Cumulative incidence of BC including baseline test
Measured: 6 years
resource expenditure
Mean costs for each attending woman in every of the following processes:
Coordination and organization; Invitation; First level mammography; Diagnostic assessment (invasive and non invasive)
Measured: 6 years
prevalence of dense breast in the target population
women with BI-RADS A, B, C, and D/total women included in the tailored arm
Measured: 6 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Oct 2020
- Study start6 Feb 2020
- Primary completionFeb 2026 (estimated)
- Study completionFeb 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Eligible women signing the written informed consent will be randomized with a 1:1:1 ratio to: Arm 1: 1-year screening interval; Arm 2: 2-year screening interval; Arm 3: tailored screening interval on the basis of breast density. Women with very dense breast (BI-RADS category D) will be referred to 1-year interval whereas women with less dense breast to 2-year interval (BI-RADS category A, B, C).
- Masking
- None (open label)
- Enrolment
- 60,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Fabio Falcini, MD, Study chair, IRST IRCCSLivia Giordano, MD, Principal investigator, A.O.U. Città della Salute e della ScienzaMarco Zappa, MD, Principal investigator, ISPRO Firenze
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04590560
- Sponsor's protocol ID
- IRST174.22
- Acronym
- MISS
- Status last verified
- Dec 2024
- First submitted
- 12 Oct 2020
- Last updated
- 9 Dec 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Dec 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- What is the Best Interval to Screen Women 45-49 and 70-74 for Breast Cancer
- ClinicalTrials.gov ID
- NCT04590560
- Acronym / sponsor ID
- MISS / IRST174.22
- Conditions
- Breast Cancer
- Keywords
- Breast cancer, screening, diagnosis, mammography
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60,000 participants (estimated)
- Lead sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSUniversity, hospital or other
- Study start
- 6 Feb 2020 (actual)
- Primary completion
- Feb 2026 (estimated)
- Study completion
- Feb 2026 (estimated)
- First posted
- 19 Oct 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Italian, multicenter, study aimed at defining the best interval for screening women 45-49 and 70-74 years for Breast Cancer (BC). This research project includes (1) a controlled, prospective randomized non-inferiority trial to determine the optimal screening interval for women aged 45-49, with and without high mammographic density, (2) a retrospective data collection, with the same purpose, on screening performed by women aged 70-74, and (3) a qualitative research to define the best communication strategy.
Detailed description
According to the 2006 European guidelines, the target age for mammography screening is 50-69 years. For women aged 40-49, effectiveness is less and less certain. For those over 70, the most important concern is overdiagnosis. In Europe, so far, both age groups have been invited to screen only in a few countries and regional areas, including some Italian regions. Recently, new European guidelines have been published, developed in the framework of the European Commission Initiative on Breast Cancer. Although with caution, they recommend screening for both women aged 45-49 and those aged 70-74. The recommended interval is 2 or 3 years in the first case and 3 years in the second. The quality of the evidence on which these recommendations are based is defined as very low. Particularly for women aged 45-49, the new European guidelines indicate the need for a research effort, based on comparative studies, on the effectiveness of different screening intervals. This responsibility also falls on Italy, which is the only European country where women aged 45-49 are invited on an annual basis. Therefore, a research project is proposed which includes (1) a controlled, prospective randomized non-inferiority trial to determine the optimal screening interval for women aged 45-49, with and without high mammographic density, (2) a retrospective data collection, with the same purpose, on screening performed by women aged 70-74, and (3) a qualitative research to define the best communication strategy.
To define the best interval for screening women 45-49 years old a three-arm multicenter randomized non-inferiority trial will be conducted. Women signing the written informed consent will be randomized with a 1:1:1 ratio to:
Arm 1: 1-year screening interval; Arm 2: 2-year screening interval; Arm 3: tailored screening interval on the basis of breast density. Women with very dense breast (Breast Imaging-Reporting and Data System -BI-RADS- category D) will be referred to 1-year interval whereas women with less dense breast to 2-year interval (Breast Imaging-Reporting and Data System -BI-RADS- category A, B, C).
Enrollment will last 2.5 years and all women will be followed for 6 years. 60,000 women will be enrolled.
The primary objective is to compare the cumulative incidence of stage 2 or higher breast cancer between different screening intervals and this will be evaluated at the end of the 6-year follow-up period.
At the same time, data from all women registered in screening archives who have had a negative mammogram at the age of 69-71 years will be collected and analyzed. The data will be retrieved up to the age of 78 and will concern screening mammograms as well as other screening procedures (e.g. biopsies) and also mammograms performed outside the program. Data from screening and outpatient information systems as well as from cancer registries will be used.
To identify the best strategy to communicate changes in screening protocols, especially when the new protocol would be less intensive than the actual one, a qualitative research will be conducted. In particular the following steps will be considered:
- Focus groups for discussing, with women from target population and health care professionals, key arguments identified in a preliminary research (i.e. scientific literature and case-studies research), with particular focus on how they should be translated into communication strategies.
- Pre-test of the study's communication material through web-based semi-structured interviews to eligible women and key-informants.
- Assessment of the effectiveness of the communication material through web-based semi-structured interviews to participants, that may bring insights on how planning communication strategies for the implementation of new screening protocols.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- Eligible women signing the written informed consent will be randomized with a 1:1:1 ratio to: Arm 1: 1-year screening interval; Arm 2: 2-year screening interval; Arm 3: tailored screening interval on the basis of breast density. Women with very dense breast (BI-RADS category D) will be referred to 1-year interval whereas women with less dense breast to 2-year interval (BI-RADS category A, B, C).
| Arm | Type | Receives |
|---|---|---|
| 1-year screening interval | No intervention | –Women will follow the normal screening program (they will be invited to screen every year) |
| 2-year screening interval | Experimental | Diagnostic Test: screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practiceWomen will be invited to screen every two years |
| 3-tailored screening interval | Experimental | Diagnostic Test: screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practicethe screening interval will be decided on the basis of breast density. Women with very dense breast (BI-RADS category D) will be referred to 1-year interval whereas women with less dense breast to 2-year interval (BI-RADS category A, B, C) |
Who may qualify
- Ages
- 45 to 49 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Women invited for their first or second mammography (45 or 46 y/o) presenting for screening;
- Willingness and ability to comply with scheduled visits;
- Written informed consent obtained prior to performing any protocol-related procedures.
Key exclusion criteria (5 listed)
- Pregnancy status;
- Personal history of prior breast carcinoma, either invasive or ductal carcinoma in situ (DCIS) diagnosis;
- Ascertained heredo-familial risk according to the standard family history used in screening programs;
- Participation in another clinical trial on BC screening;
- Inability to provide signed informed consent.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practicewomen will be screened for breast cancer using tomosynthesis and synthetic 2D mammography with an interval defined according to their randomization arm for a follow-up period of 6 years; | Diagnostic test | 2-year screening interval, 3-tailored screening interval |
Primary outcome
To compare the cumulative incidence of stage 2 or higher breast cancer between different screening intervals
Time frame: 6 years
Cumulative breast cancer risk will computed as the ratio between the number of stage 2 or higher cancers and the total number of women in the arm. The comparison between arms will be performed using the two proportion Z-test. 95% confidence intervals will also be computed
9 secondary outcomes
Participation in screening
Time frame: 6 years
contamination proportion (use of mammography) within two screening rounds (in women referred to 2-year interval)
Time frame: 6 years
Breast cancer detection
Time frame: 6 years
overall recall rate
Time frame: 6 years
rate of recall with an invasive procedure (biopsy)
Time frame: 6 years
interval Breast Cancer rate
Time frame: 6 years
cumulative Breast Cancer incidence
Time frame: 6 years
resource expenditure
Time frame: 6 years
prevalence of dense breast in the target population
Time frame: 6 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Dec 2024.
- Individual participant dataSharing planned: No
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Chiara Zingaretti contact
Fabio Falcini, MD study chair
IRST IRCCS
Livia Giordano, MD principal investigator
A.O.U. Città della Salute e della Scienza
Marco Zappa, MD principal investigator
ISPRO Firenze
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing screening for breast cancer with tomosynthesis and synthetic 2D mammography performed at different interval compared to actual clinical practice in people with Breast Cancer, run by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS at 4 sites in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 9 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Oriana Nanni (+39 0543 739100, oriana.nanni@irst.emr.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To compare the cumulative incidence of stage 2 or higher breast cancer between different screening intervals (time frame: 6 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Dec 2024.